Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.
Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses future research with CAR T-cell therapy in hematologic malignancies.
In the B-cell lymphoma space, lisocabtagene maraleucel (liso-cel) appears to be associated with low rates of severe CAR T-cell therapy–related toxicities, Hill says.
Additionally, future research efforts should compare the efficacy and safety profiles of tisagenlecleucel (Kymriah), liso-cel, and axicabtagene ciloleucel (Yescarta), explains Hill. Further investigation may also shed light on subtle differences in the makeup of each product.
Ultimately, sorting out the unique characteristics of the 3 products will help the field identify which patients will benefit most from each therapy, Hill concludes.